X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DR. REDDYS LAB - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DR. REDDYS LAB ASTRAZENECA PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 91.1 28.8 317.0% View Chart
P/BV x 13.0 3.0 438.3% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 ASTRAZENECA PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
DR. REDDYS LAB
Mar-16
ASTRAZENECA PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,2854,383 29.3%   
Low Rs6342,750 23.1%   
Sales per share (Unadj.) Rs189.6920.1 20.6%  
Earnings per share (Unadj.) Rs-0.2126.1 -0.2%  
Cash flow per share (Unadj.) Rs3.8183.0 2.1%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs68.6685.8 10.0%  
Shares outstanding (eoy) m25.00170.61 14.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.13.9 130.6%   
Avg P/E ratio x-4,712.728.3 -16,662.6%  
P/CF ratio (eoy) x249.619.5 1,280.5%  
Price / Book Value ratio x14.05.2 268.8%  
Dividend payout %015.9 0.0%   
Avg Mkt Cap Rs m23,988608,481 3.9%   
No. of employees `0001.621.7 7.2%   
Total wages/salary Rs m1,60531,874 5.0%   
Avg. sales/employee Rs Th3,040.27,244.4 42.0%   
Avg. wages/employee Rs Th1,029.21,470.9 70.0%   
Avg. net profit/employee Rs Th-3.3992.8 -0.3%   
INCOME DATA
Net Sales Rs m4,740156,978 3.0%  
Other income Rs m922,693 3.4%   
Total revenues Rs m4,832159,671 3.0%   
Gross profit Rs m-13034,587 -0.4%  
Depreciation Rs m1019,705 1.0%   
Interest Rs m0824 0.0%   
Profit before tax Rs m-13926,751 -0.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m55,237 0.1%   
Profit after tax Rs m-521,514 -0.0%  
Gross profit margin %-2.722.0 -12.4%  
Effective tax rate %-3.719.6 -18.7%   
Net profit margin %-0.113.7 -0.8%  
BALANCE SHEET DATA
Current assets Rs m2,726118,201 2.3%   
Current liabilities Rs m2,43568,368 3.6%   
Net working cap to sales %6.131.7 19.4%  
Current ratio x1.11.7 64.8%  
Inventory Days Days7460 122.9%  
Debtors Days Days4197 42.1%  
Net fixed assets Rs m1,03572,265 1.4%   
Share capital Rs m50853 5.9%   
"Free" reserves Rs m942111,548 0.8%   
Net worth Rs m1,716117,009 1.5%   
Long term debt Rs m010,690 0.0%   
Total assets Rs m4,156200,104 2.1%  
Interest coverage xNM33.5-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.10.8 145.4%   
Return on assets %-0.111.2 -1.1%  
Return on equity %-0.318.4 -1.6%  
Return on capital %021.6 0.0%  
Exports to sales %5.746.3 12.3%   
Imports to sales %6.59.0 72.2%   
Exports (fob) Rs m27072,618 0.4%   
Imports (cif) Rs m30614,050 2.2%   
Fx inflow Rs m37575,405 0.5%   
Fx outflow Rs m47027,115 1.7%   
Net fx Rs m-9648,290 -0.2%   
CASH FLOW
From Operations Rs m-840,476 -0.0%  
From Investments Rs m-146-19,421 0.8%  
From Financial Activity Rs m862-17,009 -5.1%  
Net Cashflow Rs m7094,046 17.5%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.4 5.6%  
FIIs % 15.7 35.3 44.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 9.1 15.3 59.5%  
Shareholders   12,856 75,885 16.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  VENUS REMEDIES  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Lupin up 4%(01:30 pm)

After opening the day flat, share markets in India remained rangebound and are presently trading marginally above the dotted line.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 24, 2017 03:14 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS